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0.9(95%CI:0.7-1.1), with a mean increase in total length of stays per SRE of
16.4(95%CI:13.1-19.8), 11.4(95%CI:8.0-14.8), 10.9(95%CI:8.8-13.0), 13.4(95%CI:9.3-
17.4) and 17.2(95%CI:13.6-20.7) days, respectively. For the same countries, the mean
increase in number of outpatient visits per SRE were 3.8(95%CI:2.7-4.9), 4.7(95%CI:
3.5-6.0), 1.1(95%CI:0.7-1.5), 1.3(95%CI:0.7-1.8) and 5.2(95%CI:4.0-6.5). Mean increase
in number of procedures per SRE were 10.9(95%CI:9.5-12.2), 6.9(95%CI:5.6-8.2),
4.4(95%CI:3.7-5.0), 4.7(95%CI:3.9-5.6) and 10.1(95%CI:8.8-11.4). Data by SRE type
show considerable HRU variation. CONCLUSIONS: Data indicate that SREs may
result in a mean increase of 0.8–1.0 inpatient stays with a mean total duration of
10.9–17.2 days. SREs are also linked to numerous outpatient visits and procedures.
Thus, a further reduction in the number of SREs by new bone-targeted agents
should reduce the financial burden on European health care systems.
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OBJECTIVES: The main objective of this study was to evaluate the utilisation of
antineoplastic agents in Slovak Republic during the period of 2006-2010.
METHODS: Statistical analysed data including the number of medicine packages,
DDD and financial expenditures were abstracted from the Slovak Institute of Drug
Control. Key data were provided by wholesalers due to their legal obligation to-
wards the SIDC. RESULTS: Consumption of antineoplastic agents in terms of DID
(DDD/1000 inhabitants/day) reached its highest peak in 2007 with 31,12 and the
lowest value of DID was observed in 2009 with 27,30. The total expenditures dou-
bled their volume within period of 2006-2010 from 56,021,412 € to 111,646,240 €
respectively. Number of delivered packages showed slight increase from 426,412 in
2009 to 629,782 in 2010 while price per single package was rising from 131,29 € (2006)
to 197,68 € (2008) and then decreased to 177,28 € (2010). Resulting from further study
the highest consumption in terms of DID was reached by gemcitabine (7,38 in 2006
and 7,21 in 2010), ifosfamide (5,91 in 2006 and 6,94 in 2010) and fourouracil (2,56 in
2006 and 3,26 in 2010). Expressed in financial units the most costly antineoplastic
agent in 2006 was imatinibum with 8 569 021 €, followed by rituximab with
4,896,000 € and irinotecan with 4,888,660 €. In 2010 reached paramount financial
consumption bevacizumab with 17,771,426 €, trastuzumab with 10,173,699 € and
imatinibum with 8,212,353 €. CONCLUSIONS: Expenditures for antineoplastic
agents are continually rising as a result of biological treatment establishment.
There is observed significant increase of their consuption due rheumatic diseases
treatment.
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OBJECTIVES: To review and analyse studies capturing indirect costs of treatment
in EBC. Indirect costs can form a substantial part of the treatment cost and have a
considerable impact on both the patient and society. METHODS: A literature re-
view was conducted to identify publications that included indirect costs of EBC
treatment. Indirect costs were defined as various out-of-pocket expenses or pro-
ductivity losses. Medline, Embase, EmCare, Cochrane, NHSEED, HEED and EconLit
databases were searched for published articles (January 2000 to November 2010),
using pre-specified terms. A targeted internet search also captured publications
from national websites in 10 countries. Indirect cost data were analysed to identify
trends and a gap analysis was performed. RESULTS: Only 28 studies reported rel-
evant data; they included data from economic models (based on thousands of
patients), observational studies (including 22-324 patients), databases and surveys.
The majority of studies reported indirect costs per patient; two studies reported
cost to society, but rarely as part of total costs of EBC. Data collation and reporting
was inconsistent across studies due to a variety of methods, definitions and out-
comes, which made cross-comparisons difficult. Productivity losses and out-of-
pocket costs were the most frequently reported outcomes (54% and 46% of studies,
respectively). Mortality-associated costs were captured in 11% of studies.
CONCLUSIONS: It was difficult to draw quantitative conclusions from the studies
included in this review due to the paucity of studies, lack of standardisation and
inconsistency in reporting of data. Reducing indirect costs would ease the financial
burden to society, owing to the majority of patients being of working age. Identified
cost data will be presented in the forthcoming poster; however, further work is
required.
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OBJECTIVES: To describe the current pattern of care and resource utilisation in
Europe for patients with fludarabine-refractory chronic lymphocytic leukaemia
(CLL) who are either refractory to alemtuzumab (DR) or ineligible for alemtuzumab
due to bulky lymphadenopathy (BFR) METHODS: Medical charts were reviewed
from nine sites in France, Germany, Italy, Spain and the UK. Patient charts with an
index diagnosis of DR or BFR between January 2002 and June 2008 were abstracted,
with a pre and post-index review period of 6 and 18 months respectively. RESULTS:
Data are from an interim analysis of 37 patients, 62% (n23) DR and 38% (n14)
BFR. Median time between first diagnosis and index refractory diagnosis was 5.2
years. Average age was 62.2 (range 41-77), 76% were male and average number of
co-morbidities was 2.2. Many patients (59%) died during the post index period with
median survival following diagnosis of refractory disease being 6.2 months. In the
pre-index period the average number of pharmacotherapy regimens was 0.9 (range
0-3) and in the post-index period 1.4 (range 1-4). During the 24 month review period
the most frequent single agent regimens were alemtuzumab (38% patients) and
methylprednisolone (19%). Patients receiving combination therapy most fre-
quently received rituximab (43%), mainly in combination with CHOP (16%), fludara-
bine/cyclophosphamide (11%), and bendamustine (8%). 89% of patients experi-
enced at least one treatment related adverse event, including infection (76%),
anaemia (76%), thrombocytopenia (68%) and neutropenia (62%). Average number of
post-index A&E visits was 0.8 and inpatient stays 1.9, the majority (86%) relating to
CLL or its treatment. Average inpatient stay was 11.2 days. Most patients (81%) had
multiple diagnostic investigations (average 11.5), predominantly CT scans (average
6.1) and X-rays (average 2.0). CONCLUSIONS: This study demonstrates the high
economic burden and continuing unmet clinical needs of patients with fludara-
bine-refractory CLL disease in Europe.
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OBJECTIVES: Health technology assessment (HTA) is rapidly developing in CEE
countries as new technologies are difficult to finance with scare resources. Re-
searchers often struggle with limited local epidemiologic and cost data. Therefore
transferability of resource utilization from one to other markets is becoming an
interesting topic. Late 2009 we conducted a study of advanced breast cancer in four
CEE markets (Poland, Hungary, Slovak and Czech Republics). The project aimed to
assess treatment sequence and resource used. METHODS: A common question-
naire was distributed to oncologists managing about 30 % of all oncology patients.
The assessed periods of advanced breast cancer were: a) treatment initiation; b)
routine follow-up on active treatment; c) pre-progression follow-up; and d) pro-
gression period. Data were extracted from hospital information systems and pa-
tient=s charts retrospectively. Final results covered individual treatment/disease
periods and total treatment course. RESULTS: Similar proportions of breast cancer
patients precede to second-line treatment, we found differences in patients pro-
ceeding to third line treatment. In Czech about 67 % of treated completed 3 lines
chemotherapy, in Poland it was about 30 %. In Czech and Slovakia taxane mono-
therapy represented the preferred first-line choice, Poland and Hungary favoured
combination chemotherapy. We found differences across countries such as cancer
care organization, guideline availability, number of oncologists. The above men-
tioned differences resulted in cost variations per patient from about 6 thousand
USD (excluding chemotherapy) in Poland to 12 thousand USD in Hungary. Positions
with highest relevance to cost differences were frequency and reimbursement of
in-patient management and BS/palliative care. CONCLUSIONS: As cancer care or-
ganization, treatment algorithms and reimbursement for services differ, there is
limited value in transferring cost data across CEE countries. The observed differ-
ences are especially relevant for cancer care where market access for new technol-
ogies might be un-equal in particular health care systems.
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OBJECTIVES: This research study aimed to investigate the cancer patients’ beliefs
towards disclosing T&CM use to the health care provider. METHODS: Qualitative
methodology was adapted to collect in-depth information with consented cancer
patients. The participants were recruited from the oncology wards at Penang Gen-
eral Hospital from February till July 2010. Patients with different types of cancer and
stages were recruited from the three major ethnic groups in Malaysia namely Ma-
lay, Chinese and Indians. Upon institutional ethical approval and informed con-
sent from the participants, 20 semi-structured interviews were conducted. All in-
terviews were audiotaped, transcribed verbatim and translated into English for
thematic content analysis. RESULTS: Mixed beliefs were reported and a total of 4
themes were identified from the interview analysis: fear of termination of therapy
by the physicians, fear of interaction with the orthodox medicines, perceived dis-
interest by the physicians and perception that T&CM are simple and its discussion
to the physicians is irrelevant. Most of the patients agree that T&CM disclosure is
important to avoid any interaction with the chemotherapy or radiotherapy. On the
other hand, patients believe that T&CM discussion is not important due to the lack
of physicians’ knowledge & interest in discussing T&CM. A common perception
regarding the simplicity in nature of some of the non-invasive traditional modali-
ties such as prayers, spiritual & faith healing was reported as reasons of not dis-
closing T&CM use to the physicians. CONCLUSIONS: Understanding the underly-
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